RxDoctor Payments Data

Susan Moose, DO

Internal Medicine · Woodstock, VANPI 1366641672

Payments from drug & device makers

$710in general payments, 2019–2025

Across 44 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$198
  • AstraZeneca$104
  • Novo Nordisk$82
  • Amgen$59
  • Merck$51
  • E.r. Squibb & Sons, L.L.C.$28
  • plus $188 from 10 others

What the payments were for

  • Food & beverage$68296%
  • Education$284%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$710 in reported general payments places this provider in the 70th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$9,848
Medicare patients
525
Services billed
684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban324$271,896
OzempicSemaglutide76$97,567
EnbrelEtanercept13$95,773
MounjaroTirzepatide64$72,815
XareltoRivaroxaban49$54,459
JanuviaSitagliptin Phosphate59$45,830
TrulicityDulaglutide25$41,721
Breo ElliptaFluticasone/Vilanterol72$33,606
JardianceEmpagliflozin34$32,302
Tresiba Flextouch U-200Insulin Degludec29$30,942
MyrbetriqMirabegron38$19,167
Combivent RespimatIpratropium/Albuterol Sulfate27$16,862
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$15,561
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$12,874
Spiriva HandihalerTiotropium Bromide13$12,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$198$271,896324 claims
Novo NordiskOzempic$82$97,56776 claims
AmgenEnbrel$59$95,77313 claims
MerckJanuvia, Dulera, Janumet, Belsomra$51$66,399105 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Incruse Ellipta$18$65,397125 claims
Johnson & JohnsonXarelto$15$54,45949 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Woodstock

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →